JingJiaHang BioPharma

Beijing JingJiaHang BioPharma is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the discovery and development of small molecule innovative drugs. The company focuses primarily on oncology, with a pipeline targeting well-validated pathways such as CDK4/6, PI3K, FGFR, and KRAS. Its lead candidate, JJH201601, is a selective CDK4/6 inhibitor currently in Phase 1/2 clinical trials for the treatment of advanced breast cancer. JingJiaHang leverages its internal drug design and optimization capabilities to develop highly selective and potent inhibitors for various solid tumors. The company has secured funding from prominent Chinese venture capital firms to advance its diverse portfolio of targeted therapies. Through its commitment to precision medicine, JingJiaHang aims to provide effective treatment options for patients with unmet medical needs in the cancer space.